Anap­tys­Bio's etokimab pro­vides more dis­ap­point­ing re­sults, rais­ing ques­tions about com­pound's fu­ture

The lead pro­gram for Anap­tys­Bio’s in-house pipeline has hit an­oth­er set­back.

Etokimab, an IL-33 in­hibitor, did not achieve sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in a Phase II …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER